Zhicheng He1, Yang Xia1, Shaowen Tang1, Yijiang Chen1, Liang Chen1. 1. 1 Department of Thoracic Surgery, Jiangsu Province Hospital, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 2 Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing 210029, China.
Abstract
BACKGROUND: patients of pN0 non-small cell lung cancer (NSCLC) with occult tumor cells (OTCs) in regional lymph nodes (LNs) are reported to have controversial prognostic outcomes. METHOD: We pooled pN0 NSCLC patients with OTCs in LNs and compared with those without OTCs. Patient characteristics, hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival (OS) and/or disease-free survival (DFS) were analyzed. HR greater than 1 conferred an increased hazard for patients with OTCs. RESULTS: Eighteen articles were finally enrolled in the meta-analysis and 15 studies provided sufficient data for extracting HRs for OS, resulting to 5 articles available for DFS analysis. The combined HRs of OS was 2.22 (95% CI, 1.87 to 2.64) and 2.4 (95% CI, 1.71 to 3.36) for analysis of DFS. The similar trend was obtained in the subgroup analyses regarding detection methods and study type. Interestingly, even in the analysis of mean numbers of LNs dissection (MLND) intraoperatively, both subgroups (LNs/Pts. <12 and ≥12) illustrated significant HRs of OS (HR: 3.13, 95% CI, 2.17 to 4.52 in LNs/Pts. <12 subgroup and HR: 2.09, 95% CI, 1.63 to 2.68 in LNs/Pts. ≥12). The combined HR of OS in this section was 2.37 (95% CI, 1.63 to 2.68). No publication bias was detected in all the meta-analysis sections. The prognosis of patients with OTCs is inferior to those without OTCs in the terms of OS and DFS regardless of detection methods, study types and MLND. CONCLUSIONS: The prognosis of patients with OTCs is inferior to those without OTCs in the terms of OS and DFS regardless of detection methods, study types and MLND.
BACKGROUND:patients of pN0 non-small cell lung cancer (NSCLC) with occult tumor cells (OTCs) in regional lymph nodes (LNs) are reported to have controversial prognostic outcomes. METHOD: We pooled pN0 NSCLCpatients with OTCs in LNs and compared with those without OTCs. Patient characteristics, hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival (OS) and/or disease-free survival (DFS) were analyzed. HR greater than 1 conferred an increased hazard for patients with OTCs. RESULTS: Eighteen articles were finally enrolled in the meta-analysis and 15 studies provided sufficient data for extracting HRs for OS, resulting to 5 articles available for DFS analysis. The combined HRs of OS was 2.22 (95% CI, 1.87 to 2.64) and 2.4 (95% CI, 1.71 to 3.36) for analysis of DFS. The similar trend was obtained in the subgroup analyses regarding detection methods and study type. Interestingly, even in the analysis of mean numbers of LNs dissection (MLND) intraoperatively, both subgroups (LNs/Pts. <12 and ≥12) illustrated significant HRs of OS (HR: 3.13, 95% CI, 2.17 to 4.52 in LNs/Pts. <12 subgroup and HR: 2.09, 95% CI, 1.63 to 2.68 in LNs/Pts. ≥12). The combined HR of OS in this section was 2.37 (95% CI, 1.63 to 2.68). No publication bias was detected in all the meta-analysis sections. The prognosis of patients with OTCs is inferior to those without OTCs in the terms of OS and DFS regardless of detection methods, study types and MLND. CONCLUSIONS: The prognosis of patients with OTCs is inferior to those without OTCs in the terms of OS and DFS regardless of detection methods, study types and MLND.
Entities:
Keywords:
Non-small cell lung cancer (NSCLC); early stage; hazard ratio (HR); meta-analysis; occult tumor cells (OTCs)
Authors: T Osaki; T Oyama; M Inoue; C D Gu; M Kodate; M Aikawa; T So; M Mizukami; T Mitsudomi; K Yasumoto Journal: Jpn J Thorac Cardiovasc Surg Date: 2001-09
Authors: Valerie W Rusch; Debra Hawes; Paul A Decker; Sue Ellen Martin; Andrea Abati; Rodney J Landreneau; G Alexander Patterson; Richard I Inculet; David R Jones; Richard A Malthaner; Robbin G Cohen; Karla Ballman; Joe B Putnam; Richard J Cote Journal: J Clin Oncol Date: 2011-10-11 Impact factor: 44.544
Authors: J R Izbicki; B Passlick; S B Hosch; B Kubuschock; C Schneider; C Busch; W T Knoefel; O Thetter; K Pantel Journal: J Thorac Cardiovasc Surg Date: 1996-09 Impact factor: 5.209
Authors: Maíra Rovigatti Franco; Edwin Roger Parra; Teresa Yae Takagaki; Fernando Augusto Soares; Vera Luiza Capelozzi Journal: J Bras Pneumol Date: 2008-03 Impact factor: 2.624
Authors: Christopher S Digesu; Krista J Hachey; Denis M Gilmore; Onkar V Khullar; Hisashi Tsukada; Brian Whang; Lucian R Chirieac; Robert F Padera; Michael T Jaklitsch; Yolonda L Colson Journal: J Thorac Cardiovasc Surg Date: 2017-12-14 Impact factor: 5.209